At Viridian Therapeutics, we are focused on developing best-in-class medicines for people living with autoimmune and rare diseases. Leveraging our team’s expertise in antibody discovery and engineering, we have created a robust pipeline of differentiated investigational therapeutic candidates for well-validated targets.

With a unique approach to innovation, we strategically allocate our research and development resources to address high unmet medical needs, designing therapeutics that aim to provide differentiated clinical activity, improved safety and tolerability and convenient delivery and administration for patients. Our thyroid eye disease program is an example of our drug development strategy in action, aiming to improve upon the standard-of-care and currently available treatment options within commercially established disease areas, with the ultimate goal of improving patients’ lives.

CEO Quote

Viridian was founded with a mission to significantly improve treatment options for autoimmune and rare diseases. We hope to provide people living with thyroid eye disease, in addition to other autoimmune and rare diseases, access to therapies that are safe, effective, and easy to use, so they can live full, healthy lives.

Steve Mahoney

President and CEO
Viridian Therapeutics